ED&C was published in 1962 for the treatment and removal of BCC lesions [5] . ED&C is most frequently performed with 3 successive rounds of curettage followed by electrodessication, although the rationale of performing 3 rounds is unclear. Many studies have been performed to determine the efficacy of ED&C and, depending on the exclusion criteria, between 70 and 98% of tumors do not recur [6, 7] . The recurrence rates between studies varied depending on the inclusion of head and neck lesions, the exclusion of aggressive histological subtypes, and the exclusion of lesions of larger size. However, the authors of this study are unaware of any study that has attempted to detect treatment failure in an individual patient.
We hypothesize that if BCC remains after 2 rounds of curetting and is still present in the third round of curetting the treatment has most likely failed. We therefore histologically analyze the third round of curetting to attempt to detect residual tumor. The histological examination of this specimen proved difficult as cellular architecture was lost and cytology findings were disrupted by cautery artifact. Immunohistochemical staining with Ber-EP4 was utilized to make for easier pathological recognition of tumor. The immunohistochemical staining with Ber-EP4 has been proven as a reliable source of interpretation of BCC even in the presence of inflammation [8] . Therefore, immunohistochemistry testing appears to be beneficial in predicting which patients are likely to have recurrence of BCC after ED&C.
Methods
For further details, see the supplementary materials (for all online suppl. material, see www.karger.com/doi/10.1159/000452884) [9] ( Fig. 1 ) .
Results
In all, 862 patients with BCC participated in receiving ED&C treatment with a 2-year clinical follow-up. Out of the total cases presented, 764 cases (89%) showed no evi- dence of BCC or recurrence during the 2 years of follow-up. The remaining 98 BCC patients showed evidence of BCC on the third curettage. Of these, 48 elected to participate in watchful waiting with no further treatment of the positive ED&C result. Of these 48 patients, 18 (38%) had a recurrence of BCC seen during the 2 years of followup. The remaining 50 patients with positive ED&C results elected for immediate re-excision of the residual BCC with either conventional excision (5 patients) or MMS (45 patients). Of these 50 patients, 35 (70%) had residual BCC histologically seen ( Fig. 1 ) . All first-stage MMS specimens were thawed and examined by conventional histology to evaluate for persistent tumor in the center of the block.
Discussion
In this study the authors found that submitting the third round of curettage for histological examination was an effective manner of detecting BCC treatment failures rapidly and with reasonable accuracy for patients.
This study observed a success rate of 89% for ED&C. Although finding the success rate of ED&C was not the primary purpose of this study, our success rate correlates well with previous research showing success rates between 84 and 98% [6, 7, 10, 11] . There are several potential confounding variables.
First, patients with severe comorbidities who elected against conventional excision or MMS for medical reasons were offered ED&C and were included in the study regardless of tumor characteristics. Previous literature on BCC in high-risk areas, including facial areas, recommend that ED&C should not be the primary treatment for tumors, and surgical excision is advised [7] . Due to our wide inclusion criteria, tumors that would not have been traditionally treated with ED&C (including lesions greater than 2 cm in size), lesions with aggressive histological subtype including micronodular and morpheaform BCC [12] , and lesions in high-risk locations including the Hzone [13] were included in the study, lowering our overall success rates.
Second, our study included 7 medical providers, of whom 2 were physicians, 3 were physician assistants, and 2 were nurse practitioners. The providers had between 1 and 25 years of clinical dermatological experience at the time of the study. Providers with less clinical experience may have had lower success rates in the full removal of tumor [14] and are reported to have a 5-year recurrence rate ranging from 5.7 to 18.8% when performing ED&C [15] . The literature suggests that ED&C is an appropriate technique to utilize for low-risk BCC.
Third, the detection of histological evidence of BCC in the third curettage specimen does not always signify that the tumor will recur. Previous studies have shown that positive pathological margins for tumor excisions do not always yield tumor recurrence. We, as well as previous authors, hypothesize that the inflammation associated with a surgical procedure may be sufficient to eliminate some residual tumor cells [16] . This is consistent with our study findings that only 38% of patients with untreated positive ED&C curetting had tumor recurrence within 2 years. BCC is a slow-growing tumor, and we acknowledge that if clinical follow-up were extended, more recurrences would likely be detected. However, we believe it is unlikely that the percentage would increase dramatically. Additionally, 30% of re-excised lesions showed no evidence of BCC. This may represent either inflammation destroying residual tumor, failure to detect tumor within the re-excised specimen, or false-positive results of the technique.
The identification of tumor within 70% of re-excisions of positive ED&C specimens corroborates the high specificity of the test. Finding residual tumor confirms that the procedure was successful in identifying treatment failures 70% of the time.
Zero recurrences were seen among the 764 cases with negative ED&C results. This confirms the test's high sensitivity. Our 2-year follow-up period is likely insufficient to detect all recurrences; however, zero recurrences noted in the first 2 years suggests that this technique is likely to have a high sensitivity.
Conclusion
In conclusion, the authors recommend submitting the third round of BCC curettage for routine pathological examination in combination with immunohistochemistry. In this study we found that this testing had 100% sensitivity and 70% specificity at 2 years. Submitting the third round of curetting produced by ED&C constitutes minimal additional work for the dermatologist. The technique required only a fresh curette for the third round of curettage and submission of the specimen to pathology in a standard formalin bottle. Pathological examination proved somewhat challenging, but immunohistochemistry using a Ber-EP4 stain made residual BCC interpretation possible in our study. In the authors' experience, pa-tients feel more confident with treatment after histological confirmation of success, and many patients prefer earlier definitive therapy if the treatment has possibly failed. ED&C represents one of the simplest methods of treating skin cancer, and the addition of pathological analysis may improve upon this therapy and make it even more successful.
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